ALS News Today37m
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
ALS News Today22h
Number of US ALS cases expected to increase 10% this decade: Study
The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...
ALS News Today22h
Don’t like resolutions? Try setting an intention for the new year
After columnist Dagmar Munn was diagnosed with ALS, she began setting an intention for the new year instead of formal resolutions.